Phase 2 study of clarithromycin, pomalidomide and dexamethasone(ClaPD) for patients with relapsed or refractory multiple myeloma

Phase 2

• Conditions: multiple myeloma

• Registration Number: JPRN-UMIN000024166
• Lead Sponsor: Tokai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-09-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 34

Inclusion Criteria

Not provided

Exclusion Criteria

Pregnancy or Lactation Patients with plasma cell leukemia, cardiac amyloidosis and POEMS syndrome Patients who have peripheral neuropathy or peripheral neuropathic pain of grade 3 or more Patients with severe hepatic dysfunction, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, and uncontrolled hypertension Patients with tuberculosis, herpetic keratoconjunctivitis, systemic fungal infection, and with other active infections Patients with acute myocardial infarction within 6 months, with deep venous thrombosis or with pulmonary embolism within 3 years Patients who have had a complication of active double cancer within the past 5 years HBs antigen positive,HCV antibody positive, HIV antibody positive patients Patients with a clinical picture of interstitial pneumonia or fibroid lung or an abnormal bilateral interstitial abnormality on chest CT scan regardless of the presence or absence of symptoms Other patients who are,in the opinion of the caring investigator, unfit for enrollment in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified